Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Fuzhou General Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07458919CT.gov Therapy for Advanced NSCLC With EGFR 19delins Mutation | — | Not Yet Recruiting | — | — | — |
NCT03381430CT.gov Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR | — | Unknown | — | — | — |
NCT03292133CT.gov A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02326285CT.gov Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | — | Terminated | — | — | — |
NCT02321293CT.gov A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC | — | Unknown | — | — | — |
NCT02025218CT.gov Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients | — | Terminated | — | — | — |
NCT01530334CT.gov Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment | — | Completed | — | — | — |
NCT01039948CT.gov A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01024712CT.gov Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00955695CT.gov Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
Show 24 more trialsShow fewer
NCT00616499CT.gov Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00452244CT.gov Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00455936CT.gov First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker | — | Completed | — | — | — |
NCT00411047CT.gov Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00238251CT.gov Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases | — | Completed | — | — | — |
NCT00188617CT.gov Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC | — | Completed | — | — | — |
NCT00357734CT.gov Iressa Follow-up Trial | — | Completed | — | — | — |
NCT00103051CT.gov Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00062062CT.gov Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00098462CT.gov Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00104728CT.gov Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates | — | Terminated | — | — | — |
NCT00588445CT.gov Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | — | Completed | — | — | — |
NCT00091156CT.gov Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00096486CT.gov Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00238628CT.gov A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00310154CT.gov Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00217698CT.gov Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00068653CT.gov Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00062270CT.gov Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00193336CT.gov Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00144066CT.gov A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00006049CT.gov ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00006048CT.gov ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00005806CT.gov Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gefitinib (this asset) | Fuzhou General Hospital | P3 | BB · 67 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Gefitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P2 | BBB · 73 |
| Gliosarcoma | — | P2 | BB · 71 |
| Lung Large Cell Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gefitinib in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gefitinib-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →